Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.833715
Keywords
COVID-19; tuberculosis; TB syndemic; therapeutic antibody; T cell receptor (TCR)-like antibody
Categories
Funding
- Ministry of Higher Education Malaysia [FRGS/1/2020/STG01/USM/02/12, HICoE: 311/CIPPM/4401005]
- Medical Faculty of Universiti Kebangsaan Malaysia [FF-2020-327]
Ask authors/readers for more resources
This article discusses the importance of prioritizing tuberculosis during the COVID-19 pandemic, compares COVID-19 and tuberculosis in various aspects, and emphasizes the importance of antibody therapy. The article also presents how the lessons learned from the COVID-19 pandemic can be applied to enhance antibody-based immunotherapy for tuberculosis.
2020 will be marked in history for the dreadful implications of the COVID-19 pandemic that shook the world globally. The pandemic has reshaped the normality of life and affected mankind in the aspects of mental and physical health, financial, economy, growth, and development. The focus shift to COVID-19 has indirectly impacted an existing air-borne disease, Tuberculosis. In addition to the decrease in TB diagnosis, the emergence of the TB/COVID-19 syndemic and its serious implications (possible reactivation of latent TB post-COVID-19, aggravation of an existing active TB condition, or escalation of the severity of a COVID-19 during TB-COVID-19 coinfection), serve as primary reasons to equally prioritize TB. On a different note, the valuable lessons learnt for the COVID-19 pandemic provide useful knowledge for enhancing TB diagnostics and therapeutics. In this review, the crucial need to focus on TB amid the COVID-19 pandemic has been discussed. Besides, a general comparison between COVID-19 and TB in the aspects of pathogenesis, diagnostics, symptoms, and treatment options with importance given to antibody therapy were presented. Lastly, the lessons learnt from the COVID-19 pandemic and how it is applicable to enhance the antibody-based immunotherapy for TB have been presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available